Overview

NMDA Antagonists in Bipolar Depression

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.
Phase:
Phase 4
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Cycloserine
Fluoxetine
Ketamine
Olanzapine
Quetiapine Fumarate